Graft Versus Host Disease (GvHD)Symptoms, Doctors, Treatments, Advances & More
Learn About Graft Versus Host Disease (GvHD)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Moffitt Cancer Center, Magnolia Campus
Taiga Nishihori is an Internal Medicine provider practicing medicine in Tampa, Florida. Dr. Nishihori is rated as an Elite provider by MediFind in the treatment of Graft Versus Host Disease (GvHD). He is also highly rated in 40 other conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Multiple Myeloma, Chronic Graft Versus Host Disease (cGvHD), Bone Marrow Transplant, and Bone Graft. Dr. Nishihori is currently accepting new patients.
Emory Winship Cancer Institute
Edmund Waller is a Hematologist Oncology provider practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 41 years. Dr. Waller is rated as an Elite provider by MediFind in the treatment of Graft Versus Host Disease (GvHD). He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Transplant. Dr. Waller is board certified in American Board Of Internal Medicine, 1991.
Emory Winship Cancer Institute
Amelia Langston is a Hematologist Oncology provider practicing medicine in Atlanta, Georgia. She has been practicing medicine for over 42 years. Dr. Langston is rated as an Elite provider by MediFind in the treatment of Graft Versus Host Disease (GvHD). She is also highly rated in 48 other conditions, according to our data. Her clinical expertise encompasses Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Aplastic Anemia, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Langston is board certified in American Board Of Internal Medicine, 1989.
Summary: The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
Summary: The goal of this clinical research study is to compare the effects of these drug combinations (cyclophosphamide, sirolimus, and MMF vs cyclophosphamide, sirolimus, and ruxolitinib) on the prevention of GVHD after a stem cell transplant.